AVITA Medical (AVITA Medical) Cash-to-Debt : 2.10 (As of Dec. 2023)

View and export this data going back to 2012. Start your Free Trial

What is AVITA Medical Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. AVITA Medical's cash to debt ratio for the quarter that ended in Dec. 2023 was 2.10.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, AVITA Medical could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for AVITA Medical's Cash-to-Debt or its related term are showing as below:

RCEL' s Cash-to-Debt Range Over the Past 10 Years
Min: 2.1 Med: 5063.07 Max: No Debt
Current: 2.1

During the past 13 years, AVITA Medical's highest Cash to Debt Ratio was No Debt. The lowest was 2.10. And the median was 5063.07.

RCEL's Cash-to-Debt is ranked better than
51.34% of 861 companies
in the Medical Devices & Instruments industry
Industry Median: 1.88 vs RCEL: 2.10

AVITA Medical Cash-to-Debt Historical Data

The historical data trend for AVITA Medical's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

AVITA Medical Cash-to-Debt Chart

AVITA Medical Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

No Debt

38.41

126.13

86.43

2.10

AVITA Medical Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial															86.43	39.22	38.78	21.87	2.10

Competitive Comparison of AVITA Medical's Cash-to-Debt

For the Medical Devices subindustry, AVITA Medical's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

AVITA Medical's Cash-to-Debt Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, AVITA Medical's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where AVITA Medical's Cash-to-Debt falls into.

AVITA Medical Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

AVITA Medical's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	89.057	/	(0.895	+	41.514)
	=	2.10

AVITA Medical's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	89.057	/	(0.895	+	41.514)
	=	2.10

AVITA Medical (NAS:RCEL) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

AVITA Medical Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of AVITA Medical's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

AVITA Medical (AVITA Medical) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » AVITA Medical Inc (NAS:RCEL) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

AVHHL:USA 51KA:Germany 51KA:Germany 51KB:Germany AVH:Australia

Address

28159 Avenue Stanford, Suite 220, Valencia, Los Angeles, CA, USA, 91355

Website

https://www.avitamedical.com

Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult patients in the U.S. with paediatric clinical trials and expanded indications in soft-tissue reconstruction and vitiligo underway. It is currently in roll-out across the approximately 136 U.S. burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the U.S. region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the U.S.

Executives

James Corbett	director	2 GOODYEAR, IRVINE CA 92618
Jeremy Curnock Cook	director	TARGETED GENETICS CORP, 1100 OLIVE WAY STE 100, SEATTLE WA 98101
David D O'toole	officer: CFO	1640 MARENGO STREET, LOS ANGELES CA 90033
Donna Shiroma	officer: General Counsel	C/O AVITA MEDICAL, 28159 AVENUE STANFORD, SUITE 220, VALENCIA CA 91355
Cary Guy Vance	director	800 EAST MIDDLEFIELD RD, MOUNTAIN VIEW CA 94043
Robert Mcnamara	director	C/O LDR HOLDING CORPORATION, 13785 RESEARCH BOULEVARD, SUITE 200, AUSTIN TX 78750
Michael S Perry	director, officer: Chief Executive Officer	C/O BIOTRANSPLANT INC, 196 BOSTON AVE SUITE 2800, MEDFORD MA 02155
Suzanne Crowe	director	C/O AVITA MEDICAL, 28159 AVENUE STANFORD, SUITE 220, VALENCIA CA 91355
Jan Stern Reed	director	C/O JAN STERN REED BAXTER INTERNATIONAL, ONE BAXTER PARKWAY DF2 2W, DEERFIELD IL 60015
Michael Holder	officer: Chief Financial Officer	6170 RESEARCH RD., STE 103, FRISCO TX 75034
Kathy M. Mcgee	officer: Chief Operating Officer	C/O AVITA MEDICAL, 28159 AVENUE STANFORD, SUITE 220, VALENCIA CA 91355
Sean Ekins	officer: Sr. VP of Finance	C/O AVITA MEDICAL, 28159 AVENUE STANFORD, SUITE 220, VALENCIA CA 91355
David Mcintyre	officer: Chief Financial Officer	SUITE 4 LEVEL 46 2 PARK STREET, SIDNEY C3 2000
Damien Mcdonald	director	5 MERCHANT SQUARE, NORTH WHARF ROAD, LONDON X0 W21AY
Erin Liberto	officer: Chief Commercial Officer	C/O AVITA MEDICAL, 28159 AVENUE STANFORD, SUITE 220, VALENCIA CA 91355